SGE-102: a novel therapy for refractory status epilepticus.
about
Refractory and super-refractory status epilepticus--an update.First-in-man allopregnanolone use in super-refractory status epilepticus.Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency.Neurosteroid Deficiency Associated With Epilepsy.Clinical Potential of Neurosteroids for CNS Disorders.Combination drug therapy for the treatment of status epilepticus.
P2860
SGE-102: a novel therapy for refractory status epilepticus.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
SGE-102: a novel therapy for refractory status epilepticus.
@en
type
label
SGE-102: a novel therapy for refractory status epilepticus.
@en
prefLabel
SGE-102: a novel therapy for refractory status epilepticus.
@en
P2093
P2860
P356
P1433
P1476
SGE-102: a novel therapy for refractory status epilepticus.
@en
P2093
Andrew J Cole
Kiran Reddy
Ross Reife
P2860
P356
10.1111/EPI.12286
P478
54 Suppl 6
P577
2013-09-01T00:00:00Z